Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
1 hedge funds and large institutions have $236K invested in Avidity Biosciences in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 335 closing their positions.
99.36% less ownership
Funds ownership: 99.37% → 0.01% (-99%)
100% less funds holding
Funds holding: 343 → 1 (-342)
100% less funds holding in top 10
Funds holding in top 10: 33 → 0 (-33)
100% less capital invested
Capital invested by funds: $10.8B → $236K (-$10.8B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 335
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$927M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$623M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$501M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$436M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$435M |
RNAM Hedge Fund Activity: Q1 2026 in Review
1 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2026, worth a combined $236K — down 100% from $10.8B a quarter earlier.
Sellers outnumbered buyers: 335 funds closed out of RNAM and 0 opened new positions — a net loss of 335 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $927M sold.
- 1 institutional investor held Avidity Biosciences (RNAM) as of Q1 2026, down from 343 in Q4 2025.
- Funds reported $236K of Avidity Biosciences stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Avidity Biosciences positions in Q1 2026 and 335 closed out, a net change of -335 holders.
- The largest Avidity Biosciences seller in Q1 2026 was BlackRock, an estimated $927M sold.
Based on aggregated 13F filings for Q1 2026.